Non-invasive prostate cancer diagnosing and monitoring

Technology being developed at Washington State University provides a non-invasive approach for diagnosing prostate cancer and tracking the disease’s progression.

The innovative filter-like device isolates prostate cancer indicators from other cellular information in blood and urine. It could enable doctors to determine how cancer patients are responding to different treatments … Continue reading

Share

Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML

Celgene Corporation and Agios Pharmaceuticals, Inc. announced each company has entered into collaboration agreements with Abbott to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System to identify isocitrate dehydrogenase (IDH) mutations in acute myeloid leukemia (AML) patients. Celgene is currently developing enasidenib (AG-221/CC-90007), an IDH2 mutant inhibitor, … Continue reading

Share